CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D cut its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 22.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 34,538 shares of the company’s stock after selling 10,217 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CRISPR Therapeutics were worth $1,865,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Global Trust Asset Management LLC raised its holdings in shares of CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Larson Financial Group LLC grew its position in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the period. GPS Wealth Strategies Group LLC grew its position in shares of CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares during the period. Riggs Asset Managment Co. Inc. grew its position in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the period. Finally, Principal Securities Inc. purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $41,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CRSP. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Friday, August 16th. Truist Financial lowered their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Needham & Company LLC lowered their price target on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Barclays lowered their price target on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $48.18 on Monday. The business’s 50-day simple moving average is $50.45 and its 200 day simple moving average is $56.83. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -17.71 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the prior year, the firm earned ($0.98) EPS. The firm’s quarterly revenue was down 99.3% compared to the same quarter last year. On average, equities research analysts predict that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.